By Colin Kellaher
AbbVie said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis.
AbbVie on Friday said a green light would make Rinvoq the first and only oral advanced therapy for the inflammatory disease that can cause headache, jaw pain and changes in vision, including sudden and permanent vision loss.
The North Chicago, Ill., biopharmaceutical company said the European Commission, which generally follows the CHMP's advice, is expected to make a final decision in the first half of the year.
AbbVie in late January said it expects Rinvoq revenue to top $11 billion in 2027.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 28, 2025 06:34 ET (11:34 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。